Novotech secures funding as Mercury revs pharma presence
This article was originally published in Scrip
Executive Summary
The privately held Australian contract research organization (CRO) Novotech has secured new funding by selling a 30% stake to Mercury Capital Investments, and will use the money to accelerate expansion plans.